In this week’s View, Dr. Eagle looks at the durability of pulmonary vein isolation using pulsed-field ablation, then examines genetic penetrance of dilated cardiomyopathy in genotype-positive relatives. Finally, Dr. Eagle shares some thoughts on reinterventions after CoreValve/Evolut TAVR or SAVR for treatment of severe aortic stenosis.  Subscribe to Eagle’s Eye View  

In this week’s View, Dr. Eagle looks at a scientific statement from the American Heart Association on the diagnosis and management of cardiac sarcoidosis. He then examines the temporal trends and clinical implications of ischemic stroke in women with atrial fibrillation. Finally, Dr. Eagle shares some thoughts on transcatheter aortic valve implantation in patients with high-risk symptomatic native aortic regurgitation (ALIGN-AR).  Subscribe to Eagle’s Eye View  

In this week’s View, Dr. Eagle looks at a systematic review and meta-analysis of antibiotic prophylaxis and infective endocarditis incidence following invasive dental procedures. He then examines the issue of serious bleeding in patients with atrial fibrillation using diltiazem with apixaban or rivaroxaban. Finally, Dr. Eagle shares some thoughts on low-dose colchicine for secondary prevention in atherosclerosis.  Subscribe to Eagle’s Eye View    

In this special edition of Eagle’s Eye View, Dr. Eagle introduces you to ACC24 featuring valuable insights into practice-changing updates in care. The topics include late-breaking clinical trials and science focusing on new drugs and device therapies.   Tune into ACC.org’s coverage of ACC.24 to hear from the top experts as they debate, discuss the results of the trials, share visual abstracts and find out how it all fits into your practice. The transformation of care begins at ACC.24.   ...

Drs. Kim Eagle, Dharam Kumbhani, Payal Kohli, and Ajay Kirtane review the late-breaking clinical trials from Day 3, Monday, April 7 at the American College of Cardiology Scientific Sessions 2024 in Atlanta. Trials on Monday include TARGET BP I (0:39), DEDICATE-DZHK6 (3:07), and FULL REVASC (6:31). For trial summaries, news coverage, daily video wrap-ups and more, visit ACC's Meeting Coverage Page. Follow the ACC on Social Media and use the hashtag #ACC24.  Subscribe to Eagle’s Eye View  

Drs. Kim Eagle, Dharam Kumbhani, Payal Kohli, and Ajay Kirtane review the late-breaking clinical trials from Day 2, Sunday, April 6 at the American College of Cardiology Scientific Sessions 2024 in Atlanta. Trials on Sunday include REDUCE-AMI (0:35), DanGer-Shock (3:28), ULTIMATE-DAPT (6:17) and TACT2 (10:04). For trial summaries, news coverage, daily video wrap-ups and more, visit ACC's Meeting Coverage Page. Follow the ACC on Social Media and use the hashtag #ACC24.  Subscribe to...

Drs. Kim Eagle, Dharam Kumbhani, Payal Kohli, and Ajay Kirtane review the late-breaking clinical trials from Day 1, Saturday, April 5 at the American College of Cardiology Scientific Sessions 2024 in Atlanta. Trials on Saturday include AEGIS II (0:45), VICTORION-INITIATE (2:36), RELIEVE-HF (5:27) and Step-HFpEF Dm (8:42). For trial summaries, news coverage, daily video wrap-ups and more, visit ACC's Meeting Coverage Page. Follow the ACC on Social Media and use the hashtag #ACC24.  ...

In this week’s View, Dr. Eagle looks at the timing of complete multivessel revascularization in patients presenting with non-ST-Elevation Acute Coronary Syndrome, then examines the accuracy of wearable heart rate monitors during exercise in sinus rhythm and atrial fibrillation. Finally, Dr. Eagle shares some thoughts on a multinational observation study on sports-related sudden cardiac death.  Subscribe to Eagle’s Eye View    

In this special edition of Eagle’s Eye View, Dr. Eagle highlights the latest science and innovation being presented at ACC.24 in Atlanta, Georgia from April 6-8. He gives us valuable insights into practice-changing updates in care. The topics include late-breaking clinical trials and science focusing on new drugs and device therapies.  Tune into ACC.org’s coverage of ACC.24 to hear from the top experts as they debate, discuss the results of the trials, share visual abstracts and find out...

In this week’s View, Dr. Eagle looks at sacubitril/valsartan in patients hospitalized with decompensated heart failure, then examines the prevalence and outcomes of patients with discordant high gradient aortic stenosis. Finally, Dr. Eagle shares some thoughts on current concepts regarding transcatheter treatment of tricuspid valve regurgitation.  Subscribe to Eagle’s Eye View  

In this week’s View, Dr. Eagle looks at the difference between quantitative coronary angiography versus intervascular ultrasound to guide PCI. He then discusses paclitaxel-coated balloon catheters vs uncoated balloon angioplasty for treating coronary in-stent restenosis. Finally, Dr. Eagle discusses four studies comparing percutaneous coronary intervention versus coronary artery bypass grafting in patients with left main disease with or without diabetes.  Subscribe to Eagle’s Eye View  

In this week’s View, Dr. Eagle covers various blood pressure parameters and their predictability for peripheral arterial disease (PAD) and complications, then explores the five-year outcomes of leadless pacemakers. Finally, Dr. Eagle discusses the role of palliative care in the spectrum of treating patients with heart failure.  Subscribe to Eagle’s Eye View  

This week, Dr. Eagle dedicates this episode of Eagle’s Eye View to JACC and the upcoming special issue of the Journal edited by Dr. Fuster. Dr. Eagle comments cover JACC articles on lipoprotein(a) and major adverse cardiovascular events in patients with or without baseline atherosclerotic cardiovascular disease, then explores intraoperative anemia and how it mediates sex disparity in operative mortality after coronary artery bypass grafting. Finally, Dr. Eagle talks about the value of...

In this week’s View, Dr. Eagle covers coronary calcium scores and how they predict ASCVD risk in the presence of left main disease and diabetes. He then explores TRI-SCORE and the benefits of intervention in patients with severe tricuspid regurgitation. Finally, Dr. Eagle talks about booster vaccination with SARS-CoV-2 mRNA vaccines and myocarditis in adolescents and young adults.  Subscribe to Eagle’s Eye View  

In this week’s View, Dr. Eagle covers opportunities in the postpartum period to reduce cardiovascular disease risk after adverse pregnancy outcomes. He then explores the apparent increased risk of myocardial infarction, heart failure and atrial fibrillation after spinal cord injury. Finally, Dr. Eagle talks about a systematic review and network meta-analysis of coronary angiography, intravascular ultrasound, and optical coherence tomography in the guidance of percutaneous coronary...

In this week’s View, Dr. Eagle discusses the development and validation of the American Heart Association’s PREVENT risk assessment tool. He then explores implantable hemodynamic monitors and their role in improving survival in patients with heart failure and reduced ejection fraction. Finally, Dr. Eagle talks about the 10-year outcomes of the NOTION trial regarding transcatheter or surgical aortic valve implantation.  Subscribe to Eagle’s Eye View  

In this week’s View, Dr. Eagle discusses recovery in peripartum cardiomyopathy. He then explores a systematic review and meta-analysis of the association of physical activity and cognitive decline among older adults. Finally, Dr. Eagle talks about the promises and perils of consumer mobile technologies in cardiovascular care.  Subscribe to Eagle’s Eye View  

In this week’s View, Dr. Eagle discusses the use of non–Vitamin-K antagonist oral anticoagulants versus warfarin across the spectrum of body mass index and weight. He then explores sex disparities in longitudinal use and intensification of guideline-directed medical therapy among patients with newly diagnosed heart failure with reduced ejection fraction. Finally, Dr. Eagle talks about polygenic risk in families with spontaneous coronary artery dissection.  Subscribe to Eagle’s Eye View  

In this week’s View, Dr. Eagle discusses a JACC State of the Art Review noting direct oral anticoagulants (DOACs) should not be standard treatment. He then explores various ways of guiding intervention for complex coronary lesions by optical coherence tomography (OCT) or intravascular ultrasound (IVUS). Finally, Dr. Eagle talks about a prespecified analysis of the CLEAR Outcomes Randomized Trial on the impact of bempedoic acid on total cardiovascular events.  Subscribe to Eagle’s Eye View  

In this week’s View, Dr. Eagle explores rethinking “false positive” exercise ECG Tests in patients with microvascular dysfunction. He then discusses a recent comparison of direct oral anticoagulants vs Vitamin K antagonists after transcatheter mitral valve replacement. Finally, Dr. Eagle examines a post-hoc analysis of a randomized clinical trial assessing long-term clinical and echocardiographic outcomes following the Ross procedure.  Subscribe to Eagle’s Eye View  

In this week’s View, Dr. Eagle explores using AI Large Language Models for cardiology. He then discusses arterial thromboembolism in patients with atrial fibrillation and a CHA2DS2-VASc score of 1. Finally, Dr. Eagle examines a focused update on the Advanced Cardiovascular Life Support Guidelines.  Subscribe to Eagle’s Eye View  

In this week’s View, Dr. Eagle explores the breakthroughs, trends, and major developments in cardiology over the last twelve months.  Subscribe to Eagle’s Eye View  

In this week’s View, Dr. Eagle explores the disparities in diagnosis, treatment, and outcomes of peripheral artery disease. He then discusses evolving multimodality cardiac imaging in managing transthyretin amyloid cardiomyopathy. Finally, Dr. Eagle examines the importance of residual leaks following percutaneous left atrial appendage occlusion and outcomes.  Subscribe to Eagle’s Eye View  

In this week’s View, Dr. Eagle explores longitudinal changes in pulmonary artery pressure late in life using data from the ARIC study. He then discusses the safety and tolerability of inclisiran for treatment of hypercholesterolemia. Finally, Dr. Eagle asses late gadolinium enhancement in hypertrophic cardiomyopathy and how it improves risk stratification based on current guidelines.  Subscribe to Eagle’s Eye View